Recent News
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.Read Article
ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.
Read Article
ICYMI: Channeling Bias and Cancer Risk with Biologic or Targeted Synthetic DMARDs
A retrospective US administrative claims cohort study of RA patients on tumor necrosis factor inhibitors (TNFis), non-TNFi biologics, or Janus kinase inhibitors (JAKis) found a statistically significantly higher risk of incident cancer in patients receiving rituximab, abatacept, or JAKis (compared with TNFis).
Read Article
RA: Using AI for Reading PET/CT
Dr. Bella Mehta reviews abstract OP0348 presented at the 2025 EULAR meeting in Barcelona
https://t.co/fvwnaNT3Y3 https://t.co/sFIidUzNbl
Dr. John Cush @RheumNow ( View Tweet)
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
https://t.co/78b6COM2fZ https://t.co/ucRoPER8N1
Dr. John Cush @RheumNow ( View Tweet)
"Education is not the learning of facts, but the training of the mind to think." - A. Einstein
"Education is not the learning of facts, but the training of the mind to think." - Malcolm X
Education is knowing what to do when you dont know what to do https://t.co/5CF4g78OEH
Dr. John Cush @RheumNow ( View Tweet)
Secukinumab fails in GCA phase 3 RCT. Novartis announced top-line results from the GCAptAIN study evaluating secukinumab in adults with newly diagnosed or relapsing GCA. In a steroid taper RCT, the endpoint was sustained remission at Wk 52 compared to placebo https://t.co/JuMDPvznCn
Dr. John Cush @RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies
Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/TQgahi31bh https://t.co/uFtCH9UNAq
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: TNF Inhibitor Drug-Induced Lupus
A study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical https://t.co/5ObmPws8hl
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by https://t.co/Ae8pCXz8Wh
Dr. John Cush @RheumNow ( View Tweet)
Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR
IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis
IL23i + JAKi 3.7 PY = no AE
IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections
IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis
TNFi + https://t.co/hxhTxmJpbN
Dr. John Cush @RheumNow ( View Tweet)
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%).
#EULAR2025 #OP0002 https://t.co/ulxtL1NX2Y
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Read Article
ICYMI: Secukinumab promise in PMR is real
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
Read Article
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow
#EULAR2025 #OP0033 https://t.co/nEiTWQEqsP
Dr. John Cush @RheumNow ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/bwXgrB875k
Dr. John Cush @RheumNow ( View Tweet)
Clinical determinants of multiple drug failure in D2T RA
2000+ RA cohort 250+ refractory
-Low financial status
-Cancer Hx
-CV comorbidities
-Chronic use of NSAID or GCs
Protective: Regular participation in leisure activities
#POS0030 @RheumNow #EULAR2025 https://t.co/mdePGkHU82
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: Axial Involvement in Psoriatic Arthritis
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
https://t.co/GtYn6mrWgI https://t.co/rdTJlpxWPu
Dr. John Cush @RheumNow ( View Tweet)
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm
Dr. John Cush @RheumNow ( View Tweet)
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD.
#EULAR2025 @RheumNow https://t.co/HC0skwUKQG
Dr. John Cush @RheumNow ( View Tweet)
Foot and ankle #OA is often underrecognized..
1 in 6 people over 50 have foot OA!
#EULAR2025 @RheumNow https://t.co/4wGSzC8dvi
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
PCR- Prevalence, Cost, & Risk (6.27.2025)
EULAR 2025 Rheumatology RoundUp Hosted by Dr. John J. Cush and Dr. Arthur Kavanaugh
EULAR 2025 - Day 9 podcast-
Trends and Innovations from Barcelona (6.2
Therapeutic Updates
GCA: Case by Case
Sponsored by Novartis US Medical Affairs
Dive into 4 hypothetical case studies that reveal the diverse and often complex presentations of giant cell arteritis (GCA). Each case is guided by expert commentary from Dr Michael Putman, where he offers practical insights and clinical pearls to enhance your therapeutic strategies for this multifaceted condition.
Read Post
Poster Hall
